Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results
Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...
Business Insider4d
Jefferies Remains a Sell on Novo Nordisk (0QIU)
Jefferies analyst Peter Welford maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK575.00. The company’s shares closed yesterday at DKK743.20.
Business Insider4d
UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)
UBS analyst Jo Walton maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,100.00. The company’s shares closed yesterday at DKK743.20.
New York Post4d
Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Reuters4d
Novo Nordisk to explore CagriSema weight-loss potential in new trial
COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...
Reuters4d
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug ...
The Motley Fool4d
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Bad news for Novo Nordisk (NVO-17.83%) Friday was good news for Eli Lilly (LLY 1.35%) and Viking Therapeutics (VKTX 1.83%), its two main rivals in the field of weight loss drugs. This morning ...
Bloomberg L.P.4d
Novo’s Obesity Shot Shortfall Shows Danger of Promising Too Much
Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs. The Danish ...
CNN4d
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...
Wall Street Journal4d
Novo Nordisk Shares Plunge After New Obesity Shot Disappoints
Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker ...
KTVZ5d
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...